# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral...
NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to dail...
SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasi...
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...
Shingrix (GSK's Recombinant Zoster Vaccine or RZV) is the first and only vaccine approved in this population in China.Appro...
AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct...
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Bo...
Luke joined GSK in 2017 and is currently Chief Commercial Officer, with world-wide responsibility for medicines and vaccines1. ...